A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with psoriasis

A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with psoriasis - Pharmacokinetics (PK) and the efficacy of infliximab in psoriasis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005310

Enrollment

Registered

2011-04-01

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Intravenous infusion of Infliximab (5mg/kg) at 0, 2,6,14,22 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with psoriasis vulgaris, arthritic psoriasis, pustular psoriasis or psoriatic erythroderma whose severity is over 10 points as evaluated by PASI score or BSA or DLQI.

Exclusion criteria

Exclusion criteria: Patients with severe infection, active tuberculosis, history of allergy to ingredients of infliximab or to proteins derived from mouse, demyelinating diseases and its past history and congestive heart failure. Carrier of hepatitis B virus. Patients who have a plan of immunization with vaccine.

Design outcomes

Primary

Measure	Time frame
Serum concentration of infliximab should be examined from blood samples drawn before and 30 minutes after each infusion of 0 and 2, 6, 14, 22 weeks. Serum anti-infliximab antibody will be examined from serum sample before each infusion.	—

Secondary

Measure	Time frame
PASI score should be recorded before each infusion of 0 and 2, 6, 14, 22 weeks.	—

Countries

Japan

Contacts

Public ContactFujimoto Wataru

Kawasaki Medical School Department of Dermatology

086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026